The response of hepatitis B vaccination on seronegative adults with different vaccination schedules

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 5, 2015, Pages 1102-1107

  Yao, Jun ^a   Li, Jing ^b   Chen, Yongdi ^a   Shan, Huan ^c   Dai, Xue Wei ^d   Yang, Lin Na ^b   Jiang, Zheng Gang ^a   Ren, Jing Jing ^e   Xu, Kai Jin ^e   Ruan, Bing ^e   Yang, Shi Gui ^e   Wang, Bing ^e   Xie, Tian Sheng ^e   Li, Qian ^a  

^a ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NINGBO UNIVERSITY   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d Jingdezhen Center for Disease Control and Prevention   (China)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

Adults; China; Hepatitis B vaccine; Immunization

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B ANTIBODY;

ADULT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CHINA; FEMALE; HEPATITIS B; HUMAN; IMMUNIZATION; MALE; QUESTIONNAIRE; VACCINATION; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; PROCEDURES; UTILIZATION;

ADULT; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MALE; VACCINATION;

EID: 84942410401     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.985500     Document Type: Article

References (35)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004. 350:1118-29; PMID:15014185; http://dx.doi. org/10.1056/NEJMra031087
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and Current and emerging prevention and control measures. J Viral Hepat 2004. 11:97-107; PMID:14996343; http://dx.doi.org/10.1046/ j.1365-2893.2003.00487.x
3. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global Hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34:1329-39.
4. Ganczak M, Szych Z, Korzen M. Preoperative Vaccination for HBV at Polish hospitals as a possible public health tool to limit the spread of the epidemic: a crosssectional study. Vaccine 2009. 27:3969-74; PMID:19389444; http://dx.doi.org/10.1016/j.vaccine. 2009.04.042
5. World Health Organization. Hepatitis B. http:www. who.int/Mediacentre/factsheetTs/fs204.Geneva, Switzerland: World Health Organization, 2000. Acceessed 2 June 2010.
6. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y et al. Epidemiological serosurvey of Hepatitis B in China-declining HBV prevalence due to Hepatitis vaccination. Vaccine 2013. 3 (Suppl9):J21-8; PMID:23948229; http://dx.doi.org/ 10.1016/j.vaccine.2013.08.012
7. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009. 200:39-47; PMID:19469708; http://dx.doi.org/ 10.1086/599332
8. Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl), 2009. 122:3-4; PMID:19187608
9. Chang MH, Hadzic D, Rouassant SH, Jonas M, Kohn IJ, Negro F, Roberts E, Sibal A. Acute and chronic hepatitis: working group report of the second world Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 (Suppl 2):S584-8.
10. Cindy M. Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Morb Mortal Wkly Rep 2008. 57:1-20; PMID:18802412
11. Shen LZ, Yao J. The strategy of Hepatitis b vaccine booster. Zhejiang Prev Med 2011; 12:22-5.
12. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. JHepatol 2012; 57:730-5.
13. Qi XQ, Wang Y. Chinese hepatitis B viral serum epidemiology investigation report. Beijing: People's Medical Publishing House; 2011. 49-54.
14. Daniels D, Grytdal S, Wasley A, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, TB Prevention, CDC. Surveillance for acute viral hepatitis-United States, 2007. MMWR 2009; 58 (SS03):1-27; PMID: 19478727
15. Mast EE, Mahoney FJ, Alter MJ. Progress toward elimination of hepatitis B virus transmission in the United States. Vaccine 1998. 16(Supple):S48-S51; PMID:9915035
16. Zuckerman J, Langer B. Hepatitis B vaccination in a school age population:a feasibility study. J Med Virol, 2005.76:47-54; PMID:15778966
17. Bonanni P. Implementation in Italy of a universal vaccination programme against hepatitis B. Vaccine, 1995; 13(Supple):S68-71; PMID:7571837
18. Zhang XC, Pang XH, Zhang W, Han LL, Lin CY. Prevalence of hepatitis B in Chaoyang district, Beijing in 2010. Chinese J Prevent Med 2012; 46:623-6.
19. Dun Z, Fu JY, Wang YZ, Dong SL, Xu RH, Zhao YF. Investigation on the strategy of increasing adults' inoculation rate of hepatitis B vaccine. Modern Preventive Medicine 2008, 35(11):2135-8.
20. Lian YM. Report on the innovation of china's social administration. Report on the Innovation of China's Social Administration 2012. Beijing: Social sciences academic press. 121-143.
21. Man J, Ni JZ, Wang XN, Wang JY, Xie GL. Clinic STD patients of floating population behavior survey. J QiQiHaR University Med, 2011. 17:2824-5.
22. Shi JG, Zhang T. Analysis epidemic characteristics of infectious diseases in floating population in Kunshan municipality during 1997 2003. Occup Health 2005; 1, 66-7.
23. Zhang W, Lin CY, Han LL. Different dose domestic recombinant yeast hepatitis b vaccine in adults immunization effect and influence factors. Chin J Epidemiol 2010. 31:767-70.
24. Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, Wiesinger K, Kollaritsch H. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter Travel-clinic based experience. Vaccine2001. 19:2055-66.
25. Yuan JM, Zhang JA. The effect of two hepatitis b immunization programs. Nursing Journal of Chinese People's Liberation Army 2004. 10:67-68.
26. Tran TQ, Grimes CZ, Lai D, Troisi CL, Hwang LY. Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users. Vaccine 2012.30(2):342-9; PMID:22075088
27. Saltoglu N, Inal AS, Tasova Y, Kandemir O. Comparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrob 2003; 2:10; PMID:14622443
28. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-41; PMID:15738452; http://dx.doi.org/10.7326/0003-4819-142-5-20050 3010-00008
29. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Hurlburt D, Bulkow L, Fiore AE, Bell BP, Hennessy TW. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009. 200:1390-6; PMID:19785526; http://dx. doi.org/10.1086/606119
30. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM Jr, Janssen RS, Ward JW. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1-33.
31. Hernandez-Bernal F, Aguilar-Betancourt A, Aljovin V, Arias G, Valenzuela C, de Alejo KP, Hernández K, Oquendo O, Figueredo N, Figueroa N, et al. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults. Hum Vaccin 2011. 7(10):1026-36; PMID:21941089
32. Rebedea I, Diaconescu IG, Bach D, Bartelsen O, Arndtz N. Comparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene) in healthy adults. Vaccine 2006; 24(25):5320-6; PMID:16707195; http://dx.doi. org/10.1016/j.vaccine.2006.04.018
33. Xu F, He F, Zhou BQ, Zhao QY, Yan R. Observation on immunization effect of hepatitis B vaccine in adults by different dosages and schedules. Dis Surveill 2013; 28(1):38-41.
34. Shaw Jr FE, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, Roehm Jr RR, Talley WS, Hadler SC. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine, 1989, 7(5): 425-430.
35. Kubba AK, Taylor P, Graneek B, Strobel S. Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health 2003; 6(2):106-12.